AT
The startup develops a novel immuno-virotherapy that utilizes the immune-stimulating properties of arenaviruses to target and eliminate cancer cells. This approach enhances the immune system's ability to recognize and attack tumors, providing healthcare professionals with a new treatment option for cancer patients.
Düsseldorf, Deutschland
Updated 2 months ago
Funding
$49M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a novel immuno-virotherapy that utilizes the immune-stimulating properties of arenaviruses to target and eliminate cancer cells. This approach enhances the immune system's ability to recognize and attack tumors, providing healthcare professionals with a new treatment option for cancer patients.